Economic evaluation of ALK-TKIs in ALK-positive non-small cell lung cancer: a systematic review_Chinese Journal of Evidence-Based Medicine

Authors：

XU Jiayi , DAI Zhanjing , LU Yuqiong , YANG Jing , ZHOU Wanxin , REN Ting , LU Yun ,  CHANG Feng

School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, P. R. China;

Corresponding?author：

CHANG Feng, Email: cpucf@163.com

Keywords：

ALK-TKIs; Non-small cell lung cancer; Economic evaluation; Systematic review

DOI：

10.7507/1672-2531.202208027

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the economic evaluations of anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (TKIs) in the treatment of ALK-positive non-small cell lung cancer (NSCLC). Methods PubMed, Web of Science, The Cochrane Library, CNKI, VIP and WanFang Data databases were electronically searched to collect economic evaluations of ALK-TKIs in the treatment of ALK-positive NSCLC from inception to July 2022. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies; then, a systematic review was performed. Results A total of 20 studies were included. 18 of the included studies were cost-utility analyses based on the models. The method of survival data extrapolation involved the standard parameter model and the standard parameter model with a hazard ratio adjusting. 10 studies considered or included the disutility value of adverse events. 18 studies performed cost estimation on direct costs. In China, 45% of the included studies were first-line treatment, the results showed that ALK-TKIs were less economical than chemotherapy, and second-/third-generation ALK-TKIs were less economical than crizotinib. Only 1 studies were second-line treatment, the result showed that crizotinib was more economical than chemotherapy. Conclusion The economic evaluation results of ALK-TKIs in ALK-positive NSCLC vary according to treatment stage and national scenario, and there is also room for optimization of methodological application in this field.

Citation： XU Jiayi, DAI Zhanjing, LU Yuqiong, YANG Jing, ZHOU Wanxin, REN Ting, LU Yun, CHANG Feng. Economic evaluation of ALK-TKIs in ALK-positive non-small cell lung cancer: a systematic review. Chinese Journal of Evidence-Based Medicine, 2022, 22(12): 1428-1435. doi: 10.7507/1672-2531.202208027 Copy

1.	仲佳. 《CSCO非小細胞肺癌診療指南2021》更新要點解讀. 實用腫瘤雜志, 2022, 37(1): 8-15.
2.	International Agency for Research on Cancer. Estimated age-standardized incidence rates (World) in 2020, all cancers, both sexes, all ages. Available at:https://gco.iarc.fr/today/home.
3.	邵嵐, 張沂平. 奧希替尼治療晚期非小細胞肺癌的療效及影響因素. 中國新藥與臨床雜志, 2020, 39(3): 155-161.
4.	石遠凱, 孫燕, 于金明, 等. 中國肺癌腦轉移診治專家共識(2017年版). 中國肺癌雜志, 2017, 20(1): 1-13.
5.	Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Appl Health Econ Health Policy, 2022, 20(2): 213-221.
6.	齊冉, 高勝男, 劉旭婷, 等. 間變性淋巴瘤激酶陽性非小細胞肺癌治療藥物經濟性的系統評價. 中國藥房, 2022, 33(11): 1368-1373.
7.	孫蕾, 陳平鈺, 馬愛霞. 勞拉替尼一線治療間變性淋巴瘤激酶陽性晚期非小細胞肺癌的藥物經濟學評價. 中國藥房, 2022, 33(9): 1102-1108.
8.	孫蕾, 周大創, 陳平鈺, 等. 恩沙替尼一線治療間變性淋巴瘤激酶陽性晚期非小細胞肺癌的藥物經濟學評價. 中國藥房, 2022, 33(12): 1479-1484.
9.	Li S, Li J, Peng L, et al. Cost-effectiveness of lorlatinib as a first-line therapy for untreated advanced anaplastic lymphoma kinase-positive non-small cell lung cancer. Front Oncol, 2021, 11: 684073.
10.	Huang M, Tian Y, He M, et al. Crizotinib versus chemotherapy: a real-world cost-effectiveness study in China. J Comp Eff Res, 2020, 9(2): 93-102.
11.	Li H, Lai L, Wu B. Cost effectiveness of ceritinib and alectinib versus crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Clin Drug Investig, 2020, 40(2): 183-189.
12.	Loong HH, Wong CKH, Leung LKS, et al. Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong. Cost Eff Resour Alloc, 2020, 18(1): 50.
13.	母立峰, 郭咸希, 胡艷茹, 等. 克唑替尼一線治療ALK陽性非小細胞肺癌的成本-效果分析. 中國藥師, 2020, 23(6): 1119-1123.
14.	Sivignon M, Monnier R, Tehard B, et al. Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France. PLoS One, 2020, 15(1): e0226196.
15.	Guan H, Sheng Y, Guo W, et al. Cost-effectiveness of alectinib for patients with untreated ALK-positive non-small cell lung cancer in China. Adv Ther, 2019, 36(5): 1114-1125.
16.	Liu M, Zhang L, Huang Q, et al. Cost-effectiveness analysis of ceritinib and alectinib versus crizotinib in the treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer. Cancer Manag Res, 2019, 11: 9195-9202.
17.	Peng Y, Ma F, Tan C, et al. Model-based economic evaluation of ceritinib and platinum-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Adv Ther, 2019, 36(11): 3047-3058.
18.	張龍鳳, 黃棋舒, 邱玲玲, 等. 塞瑞替尼與阿來替尼一線治療ALK陽性晚期非小細胞肺癌的成本-效用分析. 海峽藥學, 2019, 31(8): 86-89.
19.	張力, 周彩存, 趙軍, 等. 阿來替尼一線治療中國ALK陽性晚期或轉移性非小細胞肺癌的成本效果研究. 中國醫療保險, 2019, (12): 56-62.
20.	Carlson JJ, Suh K, Orfanos P, et al. Cost effectiveness of alectinib vs. crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Pharmacoeconomics, 2018, 36(4): 495-504.
21.	Zhou ZY, Mutebi A, Han S, et al. Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States. J Med Econ, 2018, 21(6): 577-586.
22.	Gourzoulidis G, Zisimopoulou O, Boubouchairopoulou N, et al. Cost-effectiveness analysis of lorlatinib in patients previously treated with anaplastic lymphoma kinase inhibitors for non-small cell lung cancer in Greece. J Health Econ Outcomes Res, 2022, 9(1): 50-57.
23.	Nilsson FOL, Asanin ST, Masters ET, et al. The cost-effectiveness of lorlatinib versus chemotherapy as a second- or third-line treatment in anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer in Sweden. Pharmacoeconomics, 2021, 39(8): 941-952.
24.	雷瑋成, 杜寶萍, 林曉泉, 等. 克唑替尼二線治療晚期非小細胞肺癌的成本效果分析. 今日藥學, 2019, 29(4): 234-236,247.
25.	Carlson JJ, Canestaro W, Ravelo A, et al. The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib. J Med Econ, 2017, 20(7): 671-677.
26.	Hurry M, Zhou ZY, Zhang J, et al. Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada. J Med Econ, 2016, 19(10): 936-944.
27.	Krijkamp EM, Alarid-Escudero F, Enns EA, et al. Microsimulation modeling for health decision sciences using R: a tutorial. Med Decis Making, 2018, 38(3): 400-422.

1. 仲佳. 《CSCO非小細胞肺癌診療指南2021》更新要點解讀. 實用腫瘤雜志, 2022, 37(1): 8-15.
2. International Agency for Research on Cancer. Estimated age-standardized incidence rates (World) in 2020, all cancers, both sexes, all ages. Available at:https://gco.iarc.fr/today/home.
3. 邵嵐, 張沂平. 奧希替尼治療晚期非小細胞肺癌的療效及影響因素. 中國新藥與臨床雜志, 2020, 39(3): 155-161.
4. 石遠凱, 孫燕, 于金明, 等. 中國肺癌腦轉移診治專家共識(2017年版). 中國肺癌雜志, 2017, 20(1): 1-13.
5. Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Appl Health Econ Health Policy, 2022, 20(2): 213-221.
6. 齊冉, 高勝男, 劉旭婷, 等. 間變性淋巴瘤激酶陽性非小細胞肺癌治療藥物經濟性的系統評價. 中國藥房, 2022, 33(11): 1368-1373.
7. 孫蕾, 陳平鈺, 馬愛霞. 勞拉替尼一線治療間變性淋巴瘤激酶陽性晚期非小細胞肺癌的藥物經濟學評價. 中國藥房, 2022, 33(9): 1102-1108.
8. 孫蕾, 周大創, 陳平鈺, 等. 恩沙替尼一線治療間變性淋巴瘤激酶陽性晚期非小細胞肺癌的藥物經濟學評價. 中國藥房, 2022, 33(12): 1479-1484.
9. Li S, Li J, Peng L, et al. Cost-effectiveness of lorlatinib as a first-line therapy for untreated advanced anaplastic lymphoma kinase-positive non-small cell lung cancer. Front Oncol, 2021, 11: 684073.
10. Huang M, Tian Y, He M, et al. Crizotinib versus chemotherapy: a real-world cost-effectiveness study in China. J Comp Eff Res, 2020, 9(2): 93-102.
11. Li H, Lai L, Wu B. Cost effectiveness of ceritinib and alectinib versus crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Clin Drug Investig, 2020, 40(2): 183-189.
12. Loong HH, Wong CKH, Leung LKS, et al. Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong. Cost Eff Resour Alloc, 2020, 18(1): 50.
13. 母立峰, 郭咸希, 胡艷茹, 等. 克唑替尼一線治療ALK陽性非小細胞肺癌的成本-效果分析. 中國藥師, 2020, 23(6): 1119-1123.
14. Sivignon M, Monnier R, Tehard B, et al. Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France. PLoS One, 2020, 15(1): e0226196.
15. Guan H, Sheng Y, Guo W, et al. Cost-effectiveness of alectinib for patients with untreated ALK-positive non-small cell lung cancer in China. Adv Ther, 2019, 36(5): 1114-1125.
16. Liu M, Zhang L, Huang Q, et al. Cost-effectiveness analysis of ceritinib and alectinib versus crizotinib in the treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer. Cancer Manag Res, 2019, 11: 9195-9202.
17. Peng Y, Ma F, Tan C, et al. Model-based economic evaluation of ceritinib and platinum-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Adv Ther, 2019, 36(11): 3047-3058.
18. 張龍鳳, 黃棋舒, 邱玲玲, 等. 塞瑞替尼與阿來替尼一線治療ALK陽性晚期非小細胞肺癌的成本-效用分析. 海峽藥學, 2019, 31(8): 86-89.
19. 張力, 周彩存, 趙軍, 等. 阿來替尼一線治療中國ALK陽性晚期或轉移性非小細胞肺癌的成本效果研究. 中國醫療保險, 2019, (12): 56-62.
20. Carlson JJ, Suh K, Orfanos P, et al. Cost effectiveness of alectinib vs. crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Pharmacoeconomics, 2018, 36(4): 495-504.
21. Zhou ZY, Mutebi A, Han S, et al. Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States. J Med Econ, 2018, 21(6): 577-586.
22. Gourzoulidis G, Zisimopoulou O, Boubouchairopoulou N, et al. Cost-effectiveness analysis of lorlatinib in patients previously treated with anaplastic lymphoma kinase inhibitors for non-small cell lung cancer in Greece. J Health Econ Outcomes Res, 2022, 9(1): 50-57.
23. Nilsson FOL, Asanin ST, Masters ET, et al. The cost-effectiveness of lorlatinib versus chemotherapy as a second- or third-line treatment in anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer in Sweden. Pharmacoeconomics, 2021, 39(8): 941-952.
24. 雷瑋成, 杜寶萍, 林曉泉, 等. 克唑替尼二線治療晚期非小細胞肺癌的成本效果分析. 今日藥學, 2019, 29(4): 234-236,247.
25. Carlson JJ, Canestaro W, Ravelo A, et al. The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib. J Med Econ, 2017, 20(7): 671-677.
26. Hurry M, Zhou ZY, Zhang J, et al. Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada. J Med Econ, 2016, 19(10): 936-944.
27. Krijkamp EM, Alarid-Escudero F, Enns EA, et al. Microsimulation modeling for health decision sciences using R: a tutorial. Med Decis Making, 2018, 38(3): 400-422.

Chinese Journal of Evidence-Based Medicine

Economic evaluation of ALK-TKIs in ALK-positive non-small cell lung cancer: a systematic review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content